Wall Street analysts expect Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPI – Get Rating) to post ($0.75) earnings per share for the current quarter, according to Zacks. Zero analysts have made estimates for Checkmate Pharmaceuticals’ earnings. Checkmate Pharmaceuticals posted earnings of ($0.88) per share during the same quarter last year, which would suggest a positive year-over-year growth rate of 14.8%. The firm is scheduled to issue its next earnings report on Monday, January 1st.
According to Zacks, analysts expect that Checkmate Pharmaceuticals will report full year earnings of ($3.15) per share for the current fiscal year, with EPS estimates ranging from ($3.24) to ($3.05). For the next financial year, analysts expect that the firm will post earnings of ($2.83) per share, with EPS estimates ranging from ($4.11) to ($1.55). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research firms that cover Checkmate Pharmaceuticals.
CMPI remained flat at $$10.50 during trading hours on Thursday. Checkmate Pharmaceuticals has a 1-year low of $2.00 and a 1-year high of $10.50. The firm’s 50 day moving average is $8.60 and its 200-day moving average is $4.95. The stock has a market capitalization of $231.40 million, a price-to-earnings ratio of -3.60 and a beta of -4.81.
In other news, major shareholder Global Strategic Fund I. Venbio sold 17,600 shares of the company’s stock in a transaction that occurred on Monday, May 9th. The stock was sold at an average price of $10.37, for a total transaction of $182,512.00. Following the transaction, the insider now directly owns 2,448,481 shares of the company’s stock, valued at $25,390,747.97. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Global Strategic Fund I. Venbio sold 399,923 shares of the company’s stock in a transaction on Tuesday, April 19th. The stock was sold at an average price of $10.42, for a total value of $4,167,197.66. Following the sale, the insider now owns 3,273,451 shares of the company’s stock, valued at approximately $34,109,359.42. The disclosure for this sale can be found here. Insiders have sold a total of 1,012,901 shares of company stock valued at $10,538,367 over the last ninety days. Company insiders own 62.60% of the company’s stock.
Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Millennium Management LLC bought a new position in shares of Checkmate Pharmaceuticals in the fourth quarter worth about $31,000. BlackRock Inc. raised its position in Checkmate Pharmaceuticals by 126.7% during the third quarter. BlackRock Inc. now owns 51,794 shares of the company’s stock valued at $205,000 after purchasing an additional 28,944 shares during the period. Finally, Decheng Capital Management III Cayman LLC bought a new position in shares of Checkmate Pharmaceuticals during the first quarter valued at approximately $4,253,000. Institutional investors own 74.56% of the company’s stock.
Checkmate Pharmaceuticals Company Profile (Get Rating)
Checkmate Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on developing and commercializing novel therapeutics for the treatment of cancer. It develops CMP-001, which is in phase II clinical trial in combination with pembrolizumab to treat patients with PD-1 refractory melanoma; combination with nivolumab to treat patients with PD-1 naïve neoadjuvant melanoma; and treatment in patients with PD-1 refractory melanoma.
- Get a free copy of the StockNews.com research report on Checkmate Pharmaceuticals (CMPI)
- The Institutions Are Rotating Into Olli’s Bargain Outlet
- Would Netflix acquiring Roku be a positive for the stock?
- Inflation, An Economic Winter Is Approaching
- Microcap Oil-Dri Corporation Is A Buy For Income Investors
- Now’s The Time To Buy MongoDB (NASDAQ: MDB)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for Checkmate Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Checkmate Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.